布地奈德联合孟鲁司特钠对小儿慢性咳嗽的治疗效果分析  

Effect analysis of budesonide combined with montelukast sodium in the treatment of chronic cough in children

作　　者：盛艳丽 张贵福 SHENG Yan-li;ZHANG Gui-fu(Department of Pediatrics,Chengwu County People's Hospital,Heze 274200,China)

机构地区：[1]成武县人民医院儿科二区,274200

出　　处：《中国实用医药》2023年第13期86-89,共4页China Practical Medicine

摘　　要：目的 分析小儿慢性咳嗽采用布地奈德联合孟鲁司特钠治疗的临床效果。方法 128例慢性咳嗽患儿,根据随机数字表法分为对照组和观察组,每组64例。对照组给予布地奈德单独治疗,观察组给予布地奈德联合孟鲁司特钠治疗。比较两组患儿临床疗效以及治疗前后血清炎症介质[免疫球蛋白E(IgE)、嗜酸性粒细胞计数(EOS)、嗜酸性粒细胞阳离子蛋白(ECP)]水平、肺功能[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、第1秒用力呼气容积占用肺活量的百分比(FEV_(1)/FVC)]、临床症状评分、慢性阻塞性肺疾病评分(CAT)。结果 观察组患儿治疗总有效率95.31%高于对照组的84.38%,差异具有统计学意义(P<0.05)。治疗后,两组患儿IgE、EOS、ECP水平均降低,且观察组患儿IgE(272.57±35.85)IU/ml、(0.42±0.08)×10^(9)/L、(6.09±1.38)μg/L均低于对照组的(432.75±48.26)IU/ml、(0.72±0.14)×10^(9)/L、(12.65±2.69)μg/L,差异具有统计学意义(P<0.05)。治疗后,观察组患儿FEV1(1.72±0.43)L、FVC(2.70±0.42)L、FEV_(1)/FVC(69.13±9.12)%均高于对照组的(1.33±0.38)L、(2.32±0.36)L、(60.22±8.12)%,差异具有统计学意义(P<0.05)。观察组患儿打喷嚏、咳痰、咳嗽症状评分分别为(1.03±0.45)、(2.61±1.21)、(2.46±1.04)分,均低于对照组的(2.51±0.35)、(4.12±1.75)、(3.83±1.35)分,差异具有统计学意义(P<0.05)。治疗后,两组患儿CAT评分均降低,且观察组患儿CAT评分(6.61±3.05)分低于对照组的(11.22±2.99)分,差异具有统计学意义(P<0.05)。结论 在小儿慢性咳嗽治疗中采用布地奈德联合孟鲁司特钠的临床效果突出,可促使患儿肺功能和炎症介质水平改善,利于缓解患儿临床症状,加快患儿病情康复。Objective To analyze the clinical effect of budesonide combined with montelukast sodium in the treatment of chronic cough in children.Methods A total of 128 children with chronic cough were divided into control group and observation group according to random numerical table,with 64 cases in each group.The control group was treated with budesonide alone,and the observation group was treated with budesonide and montelukast sodium.Both groups were compared in terms of clinical efficacy,and serum inflammatory mediators[immunoglobulin E(IgE),eosinophil count(EOS),eosinophil cationic protein(ECP)]level,lung function[forced vital capacity(FVC),forced expiratory volume in one second(FEV1),FEV1/FVC],clinical symptom score,chronic obstructive pulmonary disease assessment test(CAT)before and after treatment.Results The total effective rate of 95.31%in the observation group was higher than that of 84.38%in the control group,and the difference was statistically significant(P<0.05).After treatment,IgE,EOS and ECP levels were decreased in both groups;the observation group had IgE of(272.57±35.85)IU/ml,EOS of(0.42±0.08)×10^(9)/L,and ECP of(6.09±1.38)μg/L,which were lower than those of(432.75±48.26)IU/ml,(0.72±0.14)×10^(9)/L,and(12.65±2.69)μg/L in the control group;all the differences were statistically significant(P<0.05).After treatment,the observation group had FEV1 of(1.72±0.43)L,FVC of(2.70±0.42)L,and FEV1/FVC of(69.13±9.12)%,which were higher than those of(1.33±0.38)L,(2.32±0.36)L,and(60.22±8.12)%in the control group,all the differences were statistically significant(P<0.05).The scores of sneezing,sputum and cough were(1.03±0.45),(2.61±1.21)and(2.46±1.04)points in the observation group,which were lower than those of(2.51±0.35),(4.12±1.75)and(3.83±1.35)points in the control group,and all the differences were statistically significant(P<0.05).After treatment,CAT scores in both groups were decreased,and CAT score of(6.61±3.05)points in the observation group was lower than that of(11.22±2.99)points in th

关 键 词：慢性咳嗽 布地奈德 孟鲁司特钠 炎症介质 肺功能 

分 类 号：R725.6[医药卫生—儿科]